Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Proteomics01:33

Proteomics

A proteome is the entire set of proteins that a cell type produces. We can study proteomes using the knowledge of genomes because genes code for mRNAs, and the mRNAs encode proteins. Although mRNA analysis is a step in the right direction, not all mRNAs are translated into proteins.
Proteomics is the study of proteomes' function. It involves the large-scale systematic study of the proteome to denote the protein complement expressed by a genome. Scientist Mark Wilkins coined the term proteomics...
Protein Networks02:26

Protein Networks

An organism can have thousands of different proteins, and these proteins must cooperate to ensure the health of an organism. Proteins bind to other proteins and form complexes to carry out their functions. Many proteins interact with multiple other proteins creating a complex network of protein interactions.
These interactions can be represented through maps depicting protein-protein interaction networks, represented as nodes and edges. Nodes are circles that are representative of a protein,...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hypertension and CLL: a common and hazardous relationship.

Blood advances·2026
Same author

Fixed-duration VenO vs FCR/BR in fit patients with untreated CLL: primary analysis of the phase 3 CRISTALLO trial.

Blood·2026
Same author

Fitness beyond age: Multidisciplinary expert opinion on redefining fitness for targeted therapies in chronic lymphocytic leukemia.

HemaSphere·2026
Same author

The spectrum of tonsillar involvement in chronic lymphocytic leukemia (CLL).

Leukemia & lymphoma·2026
Same author

Australia and New Zealand consensus statement on the cardiovascular management of patients with chronic lymphocytic leukaemia treated with Bruton's tyrosine kinase inhibitors.

Internal medicine journal·2025
Same author

Real-world utilization of Bruton tyrosine kinase inhibitors in relapsed/refractory chronic lymphocytic leukemia in Australia.

Leukemia & lymphoma·2025

Related Experiment Video

Updated: Jun 17, 2026

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia
10:18

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia

Published on: October 19, 2014

Membrane proteomics for leukemia classification and drug target identification.

Philippa L Kohnke1, Stephen P Mulligan, Richard I Christopherson

  • 1University of Sydney, School of Molecular and Microbial Biosciences, Maze Crescent, Sydney, New South Wales 2006, Australia.

Current Opinion in Molecular Therapeutics
|January 15, 2010
PubMed
Summary

Understanding leukemia cell surface proteins through proteomics aids in developing targeted therapies and identifying new biomarkers for improved diagnosis and treatment of blood cancers.

More Related Videos

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

Detection of Human Leukocyte Antigen Biomarkers in Breast Cancer Utilizing Label-free Biosensor Technology
08:27

Detection of Human Leukocyte Antigen Biomarkers in Breast Cancer Utilizing Label-free Biosensor Technology

Published on: March 24, 2015

Related Experiment Videos

Last Updated: Jun 17, 2026

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia
10:18

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia

Published on: October 19, 2014

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

Detection of Human Leukocyte Antigen Biomarkers in Breast Cancer Utilizing Label-free Biosensor Technology
08:27

Detection of Human Leukocyte Antigen Biomarkers in Breast Cancer Utilizing Label-free Biosensor Technology

Published on: March 24, 2015

Area of Science:

  • Biochemistry
  • Oncology
  • Proteomics

Background:

  • Plasma membrane proteins on leukemia cells are crucial for detecting and treating hematological malignancies.
  • Engineered antibodies targeting leukemia surface molecules offer improved efficacy but can cause side effects.
  • Further understanding of leukemia cell surface protein profiles and interactions is needed for novel biomarker discovery and enhanced antibody-based therapies.

Purpose of the Study:

  • To review recent advancements in leukemia membrane proteomics.
  • To explore the potential of proteomics in identifying novel biomarkers for leukemogenesis and progression.
  • To discuss the role of surface proteins as targets for engineered antibodies and small-molecule therapeutics.

Main Methods:

  • Proteomic analysis to identify thousands of proteins in leukemia cell membrane extracts.
  • Analysis of protein abundance, interactions, and post-translational modifications.
  • Investigating the impact of chemotherapy on the surface proteome.

Main Results:

  • Plasma membrane proteome analysis can define biomarkers for leukemia diagnosis, classification, prognosis, and monitoring.
  • Proteomics provides insights into leukemia cell signaling and survival mechanisms by examining chemotherapy effects.
  • Differential expression of surface proteins on leukemia cells identifies potential therapeutic targets.

Conclusions:

  • Leukemia membrane proteomics is advancing the identification of biomarkers and therapeutic targets.
  • Future research in this area holds significant potential for leukemia classification and drug development.
  • A deeper understanding of leukemia surface proteomes will drive innovation in targeted therapies and personalized medicine.